Rituximab in the treatment of B-cell non-Hodgkin lymphoma, focus on outcomes and comparative effectiveness

Figures & data

Table 1 Treatment of diffuse large B-cell lymphoma

Trial	Treatment	Follow-up period	Results	Schema	P value
MInT^Citation8 N = 824	CHOP R-CHOP	34 months	EFS: 59% OS: 79% EFS: 84% OS: 93%	1st line	EFS P < 0.001 OS P < 0.0001
Habermann^Citation11 N = 415	CHOP R-CHOP	3 years	FFS: 46% FFS: 53%	1st line	P = 0.04
Coiffier^Citation13 N = 399	CHOP R-CHOP	7 years	EFS: 25% OS: 36% EFS: 42% OS: 53%	1st line	EFS P < 0.0001 OS P = 0.0004
Kewalramani^Citation15 N = 36	ICE R-ICE	2 years	CRR: 27% PFS: 43% CRR: 53% PFS: 54%	2nd line	PFS P = 0.25 CRR P = 0.01

Abbreviations: EFS, event-free survival; OS, overall survival; FFS, failure-free survival; CRR, complete response rate; PFS, progression-free survival.

Table 2 Treatment of follicular lymphoma

Trial	Treatment	Results	Schema	P value
Hiddemann^Citation24 N = 428	CHOP R-CHOP	RR: 90% CR: 17% RR: 96% CR: 20%	1st line	P = 0.011
van Oers^Citation25 N = 465	CHOP R-CHOP	ORR: 72% CR: 16% ORR: 85% CR: 30%	2nd line	P < 0.001
	RM OBS	PFS: 52 mo OS: 85% PFS: 15 mo OS: 77%	2nd line	PFS P < 0.001 OS P = 0.011
Marcus^Citation26 N = 321	CVP RCVP	CRR: 57% OS: 77% CRR: 81% OS: 83%	1st line	CRR P < 0.0001 OS P = 0.029
Forstpointner^Citation27 N = 65	FCM R-FCM	ORR: 70% CR: 23% ORR: 94% CR: 40%	1st line	ORR P = 0.011
Rummel^Citation28 N = 437^a	R-CHOP BR	ORR: 93% CR: 33% ORR: 94% CR: 41%	1st line	Not reported
Robinson^Citation29 N = 67^b	BR	ORR: 92% CR: 41%	2nd line	CI 95%

a 52% of the patients had follicular lymphoma, 20% had mantle cell lymphoma and 28% had other lymphoma.

b patients had indolent non-Hodgkin lymphoma and mantle cell lymphoma.

Abbreviations: CI, confidence interval; RM, rituximab maintenance; OBS, observation; BR, bendamustine with rituximab; mo, month; RR, response rate; CR, complete response; ORR, overall response rate; PFS, progression-free survival; OS, overall survival.

Table 3 Cost of diffuse large B-cell lymphoma treatment

Study	Treatment	Follow-up period	Cost
			1st line cost	Follow-up cost
Hornberger^Citation42 N = 399	CHOP R-CHOP	5 years	$3,358 $17,225	$3,950 $5,202
van Agthoven^Citation43 N = 374	CHOP	2 years	$10,254–$12,232	$9,211–$14,328
Lee^Citation41 N = 171	CHOP R-CHOP	1 year	$8,800 $22,680	$6,400 $2,311

PfreundschuhMTrumperLOsterborgACHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) GroupLancet Oncol20067537939116648042

 PubMed Web of Science ®Google Scholar

HabermannTMWellerEAMorrisonVARituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphomaJ Clin Oncol200624193121312716754935

 PubMed Web of Science ®Google Scholar

CoiffierBFeugierPMounierLong-term results of the GELA study comparing R-CHOP and CHOP chemotherapy in older patients with diffuse large B-cell lymphoma show good survival in poor-risk patientsJ Clin Oncol (Meeting Abstracts)20072518 suppl8009

 Google Scholar

KewalramaniTZelenetzADNimerSDRituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphomaBlood2004103103684368814739217

 PubMed Web of Science ®Google Scholar

HiddemannWKnebaMDreylingMFrontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study GroupBlood2005106123725373216123223

 PubMed Web of Science ®Google Scholar

van OersMHKlasaRMarcusRERituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trialBlood2006108103295330116873669

 PubMed Web of Science ®Google Scholar

MarcusRImrieKSolal-CelignyPPhase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphomaJ Clin Oncol200826284579458618662969

 PubMed Web of Science ®Google Scholar

ForstpointnerRDreylingMReppRThe addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study GroupBlood2004104103064307115284112

 PubMed Web of Science ®Google Scholar

RummelMJvon GruenhagenUNiederleNBendamustine plus rituximab versus CHOP plus rituximab in the first-line-treatment of patients with follicular, indolent and mantle cell lymphomas: results of a randomized phase III study of the Study Group Indolent Lymphomas (StiL)Blood (ASH Annual Meeting Abstracts)2008112112596

 Web of Science ®Google Scholar

RobinsonKSWilliamsMEvan der JagtRHPhase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin’s lymphomaJ Clin Oncol200826274473447918626004

 PubMed Web of Science ®Google Scholar

HornbergerJCBestJHCost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphomaCancer200510381644165115756658

 PubMed Web of Science ®Google Scholar

van AgthovenMVellengaEFibbeWEKingmaTUyl-de GrootCACost analysis and quality of life assessment comparing patients undergoing autologous peripheral blood stem cell transplantation or autologous bone marrow transplantation for refractory or relapsed non-Hodgkin’s lymphoma or Hodgkin’s disease. a prospective randomised trialEur J Cancer200137141781178911549432

 PubMed Web of Science ®Google Scholar

LeeRCZouDDemetrickDJDifrancescoLMFassbenderKStewartDCosts associated with diffuse large B-cell lymphoma patient treatment in a Canadian integrated cancer care centerValue Health200811222123018380634

 PubMed Web of Science ®Google Scholar